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CD32a has been proposed as a specific marker of latently HIV-infected CD4+ T cells. 
However, CD32a was recently found to be expressed on CD4+ T cells of healthy donors, 
leading to controversy on the relevance of this marker in HIV persistence. Here, we used 
mass cytometry to characterize the landscape and variation in the abundance of CD32a+ 
CD4+ T  cells during HIV infection. To this end, we analyzed CD32a+ CD4+ T  cells in 
primary HIV infection before and after effective combination antiretroviral therapy (cART) 
and in healthy donors. We found that CD32a+ CD4+ T cells include heterogeneous sub-
sets that are differentially affected by HIV infection. Our analysis revealed that naive (N), 
central memory (CM), and effector/memory (Eff/Mem) CD32a+ CD4+ T-cell clusters that 
co-express LILRA2- and CD64-activating receptors were more abundant in primary HIV 
infection and cART stages. Conversely, LILRA2− CD32a+ CD4+ T-cell clusters of either 
the TN, TCM, or TEff/Mem phenotype were more abundant in healthy individuals. Finally, an 
activated CD32a+ CD4+ TEff/Mem cell cluster co-expressing LILRA2, CD57, and NKG2C 
was more abundant in all HIV stages, particularly during primary HIV infection. Overall, 
our data show that multiple abundance modifications of CD32a+ CD4+ T-cell subsets 
occur in the early phase of HIV infection, and some of which are conserved after effective 
cART. Our study brings a better comprehension of the relationship between CD32a 
expression and CD4+ T cells during HIV infection.
Keywords: cD4+ T-lymphocytes, cD32a, mass cytometry cyTOF, primary hiV infection, combination antiretroviral 
therapy
inTrODUcTiOn
Effective combination antiretroviral therapy (cART) leads to the control of HIV replication and disease 
progression in HIV-infected patients (1, 2). Yet, a reservoir of latently infected CD4+ T cells persists 
despite effective cART and can rapidly re-establish high viremia following treatment interruption 
(3–6). Hence, characterization of latently infected CD4+ T cells is required for the design of thera-
peutic strategies to target HIV reservoirs. In this respect, a recent study showed that the Fc receptor 
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CD32a (also known as FcγRIIa) could be a critical marker for a 
substantial portion of the latently HIV-infected CD4+ T cells that 
harbor replication-competent proviruses (7). However, CD32a 
expression was also reported on CD4+ T  cells displaying HIV 
replication and on CD4+ T  cells from healthy donors (8–11), 
leading to controversy over the relevance of this marker for the 
characterization of latent HIV reservoirs. Moreover, CD4+ T cells 
include naive, effector, and memory populations that are differen-
tially expanded and infected by HIV, in particular during primary 
infection (12, 13). Thus, evaluating the heterogeneity of CD32a+ 
CD4+ T  cells in early HIV infection, before and after effective 
cART, could be helpful to better characterize the relationship 
between CD32a expression and HIV infection.
Here, we carried out a pan-leukocyte analysis of CD32a expres-
sion by mass cytometry to assess CD32a+ CD4+ T-cell diversity 
in primary HIV-infected patients longitudinally collected before 
and after 12  months of effective cART. We then compared dif-
ferences in the abundance of the identified CD32a+ CD4+ T-cell 
subpopulations among all HIV+ stages and under healthy condi-
tions. CD32a is generally found on myeloid cells but also appears 
to be specifically found on a subpopulation of CD4+ T cells associ-
ated with HIV persistence (7). Thus, our pan-leukocyte analysis 
included lymphoid and myeloid markers that could help to better 
characterize the phenotype and heterogeneity of CD32a+ CD4+ 
T cells. In this respect, we explored the expression of inhibitory and 
activating leukocyte immunoglobulin-like receptors (LILRs) that 
are distantly related to FcRs (14). LILRs are mainly distributed on 
myeloid cells, but some members are also found on T-cell subsets, 
similar to FcRs (15–18). Moreover, LILRs can directly regulate the 
activity of CD32a and CD64 (19–22) and play an important role 
in the dysregulation of immune responses against HIV (23–26).
Previous studies analyzed CD32 expression with only a pan-
CD32 antibody. We thus also included antibodies that discrimi-
nate CD32a from CD32b to unambiguously identify CD32a+ 
CD4+ T cells. We also investigated the expression of CD16 and 
CD64, belonging to the FcR family, within the CD32a+ CD4+ 
T-cell population.
Here, we show that primary HIV and cART stages are associated 
with a higher proportion of CD32a+ CD4+ T cells, co-expressing 
LILRA2 and CD64, among naïve (TN), central memory (TCM), 
and effector/memory (TEff/Mem) subpopulations. In addition, we 
found that a subset of activated TEff/Mem CD32a+ LILRA2+ CD57+ 
NKG2C+ cells was more abundant in all HIV stages and positively 
correlated with HIV DNA levels.
Altogether, our results unravel the diversity of CD32a+ CD4+ 
T  cells and the various phenotypic changes that occur during 
early immune responses against HIV and after effective cART.
resUlTs
Mass cytometry analysis reveals  
the Diversity of cD32a+ cD4+ T-cell 
Populations among hiV-infected Patients 
and healthy Donors
We characterized the heterogeneity of CD32a+ CD4+ T-cell 
populations in primary HIV-infected patients, before and after 
effective cART, as well as in healthy donors, using a pan-leukocyte 
mass cytometry panel of 35 markers. For this purpose, a first 
group of six patients were longitudinally sampled at the time of 
diagnosis, in the primary phase of HIV infection (primary HIV), 
and after 12 months of successful cART (HIV cART). Primary 
HIV infection referred to blood samples collected between 18 and 
30 days after HIV infection (Fiebig stage III/IV) with a high-level 
plasma viral load (number of copies/ml >  200,000) including 
parameters described by Krastinova et al. (27).
A second group of individuals was comprised of six healthy 
HIV-negative donors (healthy) (Figure 1A). Clinical characteris-
tics of these groups are shown in Table 1. The pan-leukocyte mass 
cytometry panel included markers for lymphoid and myeloid cells, 
migration and adhesion markers, and activating and inhi bitory 
immunoreceptors (Figure 1B). CD32 includes highly homologous 
isoforms (15). We thus used monoclonal antibodies that specifi-
cally recognize either CD32a (clone IV.3) or CD32b (clone 2B6) 
to avoid misinterpretation of the data (Table S1 in Supplementary 
Material). The specificity of these antibodies was confirmed by the 
detection of CD32a, but not CD32b, on monocytes and CD32b 
on only B cells (Figure S1 in Supplementary Material), in agree-
ment with previous studies (15). Thus, our results unambiguously 
reflect CD4+ T cells expressing CD32a protein on their surface.
We applied a gating strategy to select the whole CD4+ T-cell 
population (CD19−, CD3+, CD8−, and CD4+) from total leuko-
cytes (CD45+) (Figure S2 in Supplementary Material). We next 
characterized the simultaneous expression of the markers from 
our panel on total CD4+ T cells by performing a Spanning-tree 
Progression Analysis of Density-normalized Events (SPADE) (28). 
The SPADE algorithm aims to identify cell clusters with similar 
expression of selected markers, regardless of the sample cell origin 
(29). We benchmarked a set of parameters (as described in sec-
tion “Materials and Methods”) to optimize the SPADE analysis. 
We obtained 322 CD4+ T-cell clusters from all cell samples, after 
excluding a few contaminant myeloid cell clusters, and generated 
a heatmap representing their respective relative marker expression 
(Figure S3 in Supplementary Material). The range of expression for 
each marker (5th to 95th percentiles of expression) is represented 
using a gradient color scale ranging from white (not expressed) 
to dark red (highly expressed) (Figure S4 in Supplementary 
Material). Some CD4+ T-cell clusters exhibited CD32a at their 
surface at various levels, as previously reported (7).
HIV latency was proposed to be associated with increased 
expression of CD32a (7). We thus focused on CD4+ T-cell clusters 
displaying high levels of CD32a (CD32a+), indicated on the heatmap 
in red and dark red (Figures S3 and S4 in Supplementary Material), 
and generated a second heatmap representing only CD32a+ CD4+ 
T-cell clusters (Figure  2A). The total number of cells (from all 
conditions) associated with each CD32a+ CD4+ T-cell cluster was 
quantified (Figure S5 in Supplementary Material). Characterization 
of these clusters revealed heterogeneous phenotypes within 
CD32a+ CD4+ T cells that were associated with naive (TN: CCR7+ 
CD45RA+), central memory (TCM: CCR7+ CD45RA−), and effector/
memory (TEff/Mem: CCR7− CD45RA−) subsets (Figure 2A). Further 
analysis showed that among CD32a+ CD4+ T-cell clusters, HIV+ 
patients under cART displayed a significantly higher proportion 
of TCM than TN (p = 0.016) (Figure S6 in Supplementary Material). 
FigUre 1 | Study design and mass cytometry panel. (a) Schematic representation of the study design. Two groups of individuals were studied. The first group 
corresponds to HIV-infected patients collected during primary HIV infection, diagnosed within 30 days post-infection (primary HIV), and after 12 months of 
combination antiretroviral therapy (HIV cART). The second group corresponds to healthy donors (healthy). Blood samples were collected from the two groups of 
individuals and PBMCs isolated for mass cytometry analysis. (B) Pan-leukocyte mass cytometry panel, including 35 parameters, used to characterize CD32a+ CD4+ 
T-cell diversity in leukocytes from PBMC samples. Markers used for Spanning-tree Progression Analysis of Density-normalized Events (SPADE) clusterization of 
CD4+ T cells are indicated in blue. Non-SPADE clustering markers are indicated in gray.
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These subsets of CD32a+ CD4+ TCM and TN represented an average 
of 5.25 and 1.01% of HIV cART CD4+ T cells, respectively. CD32a 
was also expressed on CD4+ T cells from healthy donors (Figure 
S6 in Supplementary Material). In healthy donors, the proportion 
of CD32a+ CD4+ T cells was significantly higher among TCM than 
TN (p =  0.034), similar to HIV cART patients, representing an 
average of 3.37 and 1.20% of CD4+ T  cells, respectively (Figure 
S6 in Supplementary Material). The percentages of CD32a+ CD4+ 
TN, TCM, and TEff/Mem also varied in primary HIV+ patients, but the 
differences were not statistically significant.
These results show that CD32a+ CD4+ T cells are present in 
HIV+ patients, as well as healthy donors, and are contained within 
heterogeneous populations showing naive, central memory, or 
effector/memory phenotypes that may be differentially affected 
by HIV infection.
clusters of lilra2+ cD32a+ cD4+ T cells 
are More abundant in hiV-Primary 
infection and after effective carT
We determined whether HIV infection was associated with 
specific CD32a+ CD4+ T-cell clusters by characterizing the 
differentially abundant clusters (DACs) between two conditions, 
including primary HIV vs. healthy donors, HIV cART vs. healthy 
donors, and primary HIV vs. HIV cART (Figure 2B). DACs were 
identified based on their cell abundance relative to that of CD32a+ 
CD4+ T cells. DACs showing a significantly (p < 0.05) higher cell 
proportion in each HIV+ stage (primary HIV and cART) vs. 
healthy donors (red arrows) were selected for further analysis.
Five DACs (#5, #258, #136, #86, and #261) were significantly 
more abundant in HIV+ patients in primary infection and after 
cART than in healthy donors (Figures  3A,B). One, cluster #5, 
was also significantly (p = 0.045) more abundant in primary HIV 
infection than after cART (Figure  3A). This cluster displayed 
an activated TEff/Mem (CCR7− CD45RA− HLA-DRmid CD38+) 
phenotype, expressing the activating immune-receptor LILRA2 
and the high-affinity IgG receptor CD64. Cluster #5 was also 
characterized by the expression of CD57, which is associated 
with replicative senescence, NKG2C-activating receptor, and the 
HIV-restriction factor CD317 (also known as BST2 or Tetherin) 
(Figure 3A).
We also analyzed the phenotype of the four other DACs that 
showed statistically significant differences in abundance between 
HIV-infected patients and healthy donors (Figure 3B). Two (#258 
TaBle 1 | Summary of patient and subject clinical parameters.
Primary hiV 
(n = 6)
→ hiV carT 
(n = 6)
healthy 
(n = 6)
Age 34
(24–47)
35
(25–48)
35
(25–45)Median (min–max), in years
Gender M M M
Days since HIV-1 diagnosis 28
(18–29)
361
(290–372)
N/A
Median (min–max), in days
Treatment None cART None
HIV DNA 3.55
(2.90–3.90)
2.21
(1.39–2.74)
N/A
Median (min–max), in  
log10 copies/106 PBMCs
HIV RNA load 6.67
(5.47–7.26)
1
(1–1.63)
N/A
Median (min–max), in  
log10 copies/ml of plasma
CD4+ T-cell count 470
(258–669)
843
(570–1,247)
856
(634–1,412)Median (min–max),  
in 103 cell/μl of blood
Twelve Caucasian men were involved in this study to constitute two groups of 
individuals. These groups are composed of six primary HIV-infected patients before 
treatment (primary HIV) and after 12 months of combination antiretroviral therapy 
(HIV cART) and six healthy subjects (healthy). The gender and median patient age, 
days since HIV-1 diagnosis, total DNA level, RNA viral load, and CD4+ T-cell count are 
indicated for each group.
cART, combination antiretroviral therapy; N/A, not applicable; M, male.
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portion of T  cells from healthy donors were previously found 
to express CD32 (9–11). We thus focused on DACs that were 
significantly less abundant in primary HIV and cART patients 
than in healthy donors (Figures 3C,D).
Six DACs (#241, #162, #312, #243, #188, and #142) were 
significantly less abundant in all HIV+ stages than in healthy 
donors (Figures 3C,D). Clusters #241 and #162 were also signifi-
cantly less abundant in primary HIV infection than after cART 
(Figure 3C). These clusters displayed a resting TEff/Mem phenotype 
(CCR7− CD45RA− HLA-DRmid CD38−) and highly expressed 
CD161 (Figure 3C). Moreover, they also showed medium expres-
sion of CD64, CX3CR1, and CD33 (high for cluster #241). Cluster 
#241 also displayed medium expression of CD317, CD32b, and 
CD11c (Figure 3C).
The four other DACs (#312, #243, #188, and #142) showed no 
statistical difference in abundance between primary HIV-infected 
patients before and after effective cART (Figure 3D). Two DACs, 
clusters #312 and #243, were associated with a resting TCM phe-
notype (CCR7+ CD45RA− HLA-DRmid CD38−), with medium 
expression of CD64, CX3CR1, LILRB4, and CD33 for cluster 
#243 (Figure 3D). Finally, clusters #188 and #142 displayed an 
activated (HLA-DRmid CD38+) and resting (HLA-DRmid CD38−) 
TN profile (CCR7+ CD45RA+/mid), respectively. They also showed 
expression of CD64, CX3CR1, and CD33, with cluster #188 co-
expressing LILRB4 and PD-L1 and cluster #142 co-expressing 
CD86, CD161, and CD14.
Our data show that the proportion of CD32a+ CD4+ T-cell 
clusters with specific resting memory or resting/activated naive 
phenotypes in healthy donors are significantly reduced during HIV 
infection. In contrast to the HIV-associated subsets, these clusters 
showed low expression of CD64 and no expression of LILRA2. This 
suggests that LILRA2 expression may be associated with CD32a+ 
CD4+ T  cells that are preferentially preserved, differentiated, 
and/or expanded from primary HIV infection to the cART stage. 
Finally, our data also demonstrate that TEff/Mem CD32a+ LILRA2− 
CD161+ clusters are less represented during primary HIV infection 
than under cART and healthy conditions, suggesting that early 
infection induces their depletion or phenotypic modification.
cell abundance of the lilra2+ cD32a+ 
cD4+ T-cell cluster #5 correlates With  
hiV Dna levels
The total amount of HIV DNA in PBMCs has been shown to 
correlate with the size of HIV reservoir (30). Therefore, we next 
investigated whether the abundance of CD32a+ CD4+ T cells was 
associated with HIV DNA in PBMCs. There was no correlation 
between HIV DNA levels and the percentage of total CD32a+ cells 
among CD4+ T  cells (Figure S7A in Supplementary Material), 
in accordance with previous studies (10, 11). Thus, we further 
investigated the association of HIV DNA levels with the abun-
dance of cell populations at the cluster level. Correlations were 
based on the number of cells associated with each cluster relative 
to the number of cells in the parent population, corresponding, 
respectively, to CD32a+ CD4+ T cells or CD4+ T cells.
Among the CD32a+ CD4+ T-cell clusters, 10 significantly 
(Pearson correlation coefficient > 0.65, p < 0.05) correlated with 
and #136) also displayed a TEff/Mem phenotype (CCR7− CD45RA−), 
expressing LILRA2, CD64, and CX3CR1 (Figure 3B). However, 
cluster #258 showed an activated phenotype (HLA-DR+ CD38mid), 
with co-expression of CD57, NKG2C, CD317, CD161, CD33, and 
CD11c, whereas cluster #136 displayed a resting profile (HLA-
DRmid CD38−), with medium expression of PD-L1. Finally, cluster 
#86 showed a resting TCM phenotype (CCR7mid CD45RA− HLA-
DRmid CD38−), co-expressing LILRA2, CD64, and CX3CR1, and 
cluster #261 was associated with an activated TN profile (CCR7+ 
CD45RAmid HLA-DRmid CD38mid), co-expressing immunomodu-
latory receptors LILRA2, CD64, CX3CR1, LILRB4, CD32b, 
CD161, CD33, costimulatory/inhibitory molecules CD86 and 
PD-L1, and HIV-restriction factor CD317.
Our analysis demonstrates that specific LILRA2+ CD64+ 
CD32a+ CD4+ T-cell clusters, characterized by naive and memory 
T-cell phenotypes, were more abundant in HIV+ patients from 
the early phase of infection. Among these clusters, the activated 
TEff/Mem CD32a+ LILRA2+ CD57+ NKG2C+ cluster (#5) showed 
a gradient of abundance which was lowest in healthy samples, 
higher in those undergoing cART, and highest in those with a 
primary HIV infection. These data suggest that the increase in 
the proportion of the activated TEff/Mem CD32a+ LILRA2+ CD57+ 
NKG2C+ subset occurred early during HIV infection and that 
it remained elevated, but to a lesser extent, after effective cART.
The Proportion of the lilra2− cD32a+ 
cD4+ T-cell subset is lower in Primary 
hiV infection and carT stages Than in 
healthy condition
We also investigated whether some clusters of CD32a+ CD4+ 
T cells were more abundant in healthy individuals, since a small 
FigUre 2 | Phenotypic landscape and variation in cell abundance of CD32a+ CD4+ T-cell clusters from HIV-infected and healthy donor samples. (a) Heatmap 
showing relative marker expression for CD32a+ CD4+ T-cell clusters. The mean of the median expression of each marker was determined and classified using  
a five-tiered color scale, from white (not expressed) to dark red (highly expressed), according to their range of expression (5th to 95th percentile) throughout the 
dataset. Clustering markers are shown in blue. Hierarchical clustering of both the cell clusters and clustering markers were performed and represented using 
dendrograms. (B) Chart summarizing the clusters showing significantly different cell abundances between the biological conditions [differentially abundant  
clusters (DACs)]. For each comparison of corresponding DACs, red arrows indicate an increase in the abundance of the cell cluster, whereas green arrows  
indicate a decrease in abundance, for the left condition relative to that on the right.
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HIV DNA levels (Figure  4A). Six were differentially abundant 
between HIV+ and healthy conditions (Figure  2B). Among 
them, clusters for which the abundance negatively correlated 
with HIV DNA levels were those previously identified as rest-
ing TEff/Mem #241 and #162, TCM #312 and #243, and TN #142 
clusters. However, these clusters did not negatively correlate 
with HIV DNA levels among CD4+ T-cell clusters (Figure 4B). 
Our analysis revealed only cluster #5 was differentially abundant 
between HIV+ and healthy conditions and positively correlated 
with HIV DNA levels (Pearson correlation coefficient =  0.690, 
p = 0.0015) (Figure 4; Figure S7B in Supplementary Material). 
This correlation was observed among both CD32a+ CD4+ and 
CD4+ T-cell clusters (Figure 4). Cluster #5 also showed unique 
significant differences in abundance relative to CD4+ T  cells 
between all conditions (Figure S8A in Supplementary Material). 
This activated TEff/Mem CD32a+ LILRA2+ CD57+ NKG2C+ subset 
represented an average of 0.37% of primary HIV CD4+ T cells 
vs. only 0.1 and 0.01% under HIV cART and healthy conditions, 
respectively (Figure S8A in Supplementary Material). We also 
determined the percentages of cells (relative to CD4+ T  cells) 
associated with the clusters described in Figure 3 (Figures S8B–D 
in Supplementary Material).
We further characterized the phenotype of this activated 
TEff/Mem CD32a+ LILRA2+ CD57+ NKG2C+ subset by quantifying 
differences in marker expression between this subset and all CD4+ 
T cells by the Kolmogorov–Smirnov distance (KS) (Figure S9 in 
Supplementary Material). CD57 showed the highest difference 
between cluster #5 and the whole set of CD4+ T cells (KS = 0.9214). 
The next most distant markers were CCR7 (KS = 0.6434), CD32a 
(KS =  0.6387), CD45 (KS =  0.5899), NKG2C (KS =  0.5892), 
CD38 (KS = 0.4817), HLA-I (KS = 0.4619), CD64 (KS = 0.3763), 
LILRB1 (KS = 0.3130), and LILRA2 (KS = 0.3036). These results 
are consistent with the phenotypic characterization of cluster #5 
displayed in the heatmap representation (Figure 2A). Moreover, 
these data provide further details on the specificity of the markers 
associated with this cluster that could be helpful for cell sorting.
Overall, our results show that the abundance of the LILRA2+ 
CD32a+ CD4+ T-cell cluster, displaying an activated TEff/Mem pheno-
type and co-expressing CD57, NKG2C, and CD317 positively 
correlated with HIV DNA levels.
FigUre 3 | Characterization of CD32a+ CD4+ T-cell clusters showing significant differences in cell abundance for HIV+ conditions. (a) Graph showing the cell 
abundance of the cluster #5 relative to CD32a+ CD4+ T cells for all samples, and heatmap representation illustrating the phenotype of this cluster. Cluster #5 was 
significantly more abundant under primary HIV (circle) and HIV cART (square) than healthy (triangle) conditions. This cluster was also more abundant under primary 
HIV than HIV cART conditions. (B) Graph showing the cell abundance of the clusters #258, #136, #86, and #261 relative to CD32a+ CD4+ T cells for all samples, 
and heatmap representation of the phenotype of these clusters. These clusters were significantly more abundant under primary HIV and HIV cART than healthy 
conditions. (c) Graph showing the cell abundance of the clusters #241 and #162 relative to CD32a+ CD4+ T cells for all samples, and heatmap representation 
showing the phenotype of these clusters. Clusters #241 and #162 were significantly less abundant under primary HIV and HIV cART than healthy conditions.  
These clusters were also less abundant under primary HIV than HIV cART conditions. (D) Graph showing the cell abundance of the clusters #312, #243 #188, and 
#142 relative to CD32a+ CD4+ T cells for all samples, and heatmap representation showing the phenotype of these clusters. These clusters were significantly less 
abundant under primary HIV and HIV cART than healthy conditions. In the abundance graph representations, samples from the same HIV-infected patients were 
represented in the same color. For each condition, the mean cell abundance is indicated (black lines). Statistical differences between conditions were calculated 
using an unpaired Student’s t-test with a p-value threshold of 0.05. For heatmap representations, the relative marker expression for each cluster was indicated by  
a five-tiered color scale ranging from white (not expressed) to dark red (highly expressed).
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DiscUssiOn
A previous study has proposed CD32a as a specific marker of 
CD4 T latently infected cells (7). However, CD32a was also 
reported on CD4+ T cells showing HIV replication and on CD4+ 
T cells from healthy donors; suggesting a complex relationship 
between HIV infection and CD32a expression on CD4+ T cells 
(8–11). Here, we aimed to better characterize the heterogeneity 
and abundance of CD32a+ CD4+ T  cells in various conditions 
including primary HIV infection, cART, and healthy conditions. 
Indeed, CD4+ T cells include various subsets that are selectively 
activated during early HIV infection, resulting in changes in 
protein expression and clonal expansion. In addition, CD4+ 
T-cell subsets are differentially infected and killed by HIV, thus 
increasing the complexity of their dynamics during the infection.
High-dimensional analyses are critical for disentangling the 
numerous cellular and molecular events induced by HIV infec-
tion. Our mass cytometry panel included typical and atypical 
T-cell markers that may be associated with the uncommon 
expression of CD32a on CD4+ T  cells during HIV infection. 
Moreover, all previous studies carried out flow-cytometry analy-
sis using a pan anti-CD32 antibody that binds both CD32a and 
CD32b receptors, possibly leading to misinterpretation of the 
data (7, 10). We thus included antibodies that make it possible 
FigUre 4 | Correlation analyses of CD32a+ CD4+ and CD4+ T-cell cluster abundances with HIV DNA levels. (a,B) Correlations were based on the number of cells 
associated with each cluster relative to the number of cells in the parent population, corresponding to CD32a+ CD4+ T cells or CD4+ T cells, respectively. Clusters 
having an abundance positively (right) or negatively (left) correlated with total HIV DNA levels are represented in red. The two-dimensional charts represent the 
association between the cell abundance and total HIV DNA for each cluster using the Pearson correlation coefficient and associated p-value. Each dot in the 
representation corresponds to a cell cluster. Significantly correlated clusters are indicated in red with a Pearson correlation coefficient > 0.65 and a p-value < 0.05. 
The size of the dot is proportional to the number of cells of the whole dataset associated with the cluster. The Pearson correlation coefficient is represented on the 
X-axis and the associated p-value, shown as −log10, on the Y-axis. Cluster #5 is indicated in bold.
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to clearly distinguish CD32a from CD32b isoforms (Figure S1 in 
Supplementary Material). Hence, our data unambiguously reflect 
CD4+ T cells expressing CD32a, but not CD32b, protein on their 
surface (Figure 2A).
Our study showed that CD32a+ CD4+ T cells can be found not 
only in HIV+ patients but also in healthy donors and encompass 
heterogeneous populations. Indeed, we detected CD32a+ CD4+ 
T cells from HIV-infected patients and healthy donors within TCM, 
TEff/Mem, and TN subsets. Under cART and healthy conditions, the 
proportion of CD32a+ TCM was significantly higher than CD32a+ TN 
(Figure S6 in Supplementary Material). These data are in accordance 
with previous reports showing CD32 expression on small subsets 
of CD4+ or CD8+ T cells from healthy donors (9–11). Moreover, 
we also showed that some CD32a+ CD4+ T-cell subsets were more 
abundant under healthy than HIV+ conditions (Figures  3C,D). 
Such subsets of CD32a+ CD4+ T cells may be more prone to deple-
tion or modification of protein expression during HIV infection, 
resulting in the negative correlation of their abundance with total 
HIV-DNA levels observed in our study (Figure 4A).
We analyzed the abundance of CD32a+ CD4+ T-cell clusters 
in HIV+ patients in the primary-infection phase and after effec-
tive cART and compared them with those from healthy donors 
(Figure 3). CD32a+ CD4+ T-cell clusters co-expressing LILRA2 
and CD64 were highly represented in all HIV+ stages, in contrast 
to healthy conditions. Conversely, the proportion of CD32a+ CD4+ 
T-cell clusters with lower CD64 and negative LILRA2 expression 
was higher under healthy conditions. These data suggest that 
LILRA2 expression may be associated with CD32a+ CD4+ T cells 
that are preserved, differentiated, and/or expand in primary HIV 
infection and maintained after effective cART. A previous study 
reported that LILRA2 is expressed by monocytes and neutrophils 
and recognizes bacterially cleaved immunoglobulin, leading to 
the activation of signaling pathways and subsequent immune 
responses (31). Thus, CD64+ LILRA2+ CD32a+ CD4+ T-cell popu-
lations that increase in proportion during primary HIV infection 
and cART treatment may be more prone to activation through 
the engagement of CD32a, CD64, or LILRA2 activating receptors. 
Given that CD4+ T  cells can uptake membrane fragments dur-
ing cell–cell interactions through a process named trogocytosis 
(32, 33), it is also possible that the expression of uncommon myeloid 
markers on the surface of CD32a+ CD4+ T cells could result from 
intercellular membrane exchanges. Analysis of the distribution of 
these molecules on CD4+ T cells by confocal microscopy but also 
characterization at mRNA level should be helpful to determine 
the implication of trogocytosis in the unusual markers found on 
CD32a+ CD4+ T cells.
Among LILRA2+ CD32a+ CD4+ T-cell clusters that were more 
abundant in HIV+ stages, only cluster #5 was also more abundant 
during primary HIV infection than during cART treatment. 
This cluster showed an Eff/Mem phenotype and displayed high 
expression of CD38, CD57, NKG2C, and CD317 restriction fac-
tor for HIV that retains nascent virions at the cell surface, thus 
preventing their release (34). Expression of NKG2C was reported 
on a rare CD4+ T-cell population in pathological situations, 
such as multiple sclerosis or cytomegalovirus (CMV) infection 
(35, 36). In addition, the expression of CX3CR1 was reported on 
CMV-specific CD4+ T cells in patients showing HIV-associated 
atherosclerosis (37). In this regard, CMV serological status was 
assessed in HIV+ samples and demonstrated that patients were 
already positive for IgG (but not IgM), indicating they were not 
in the primary stage of CMV infection. In addition, no clinical 
parameters associated with CMV reactivation were detected dur-
ing our study, ruling-out the implication that cluster abundance 
modification was a result of CMV activity.
Previous studies based on classical CD4+ T-cell markers could 
not detect any correlation between the percentage of CD32+ CD4+ 
T-cell subsets and the amount of HIV DNA (10, 11). We found a 
single cluster (#5) that positively correlated with HIV DNA levels, 
not only among the CD32a+ CD4+ T-cell clusters but also the CD4+ 
T-cell clusters (Figure 4; Figure S7B in Supplementary Material). 
These results suggest that not all CD32a+ CD4+ T cells are associ-
ated with HIV DNA, but only specific subsets, including the 
activated TEff/Mem CD32a+ LILRA2+ CD57+ NKG2C+ subset. The 
abundance of this subset was significantly higher in HIV+ samples 
than those from healthy donors and also higher in primary HIV 
infection than after cART. It was previously reported that the total 
amount of HIV DNA reflects the global HIV reservoir (30). Thus, 
due to its formation during the early stages of HIV infection and its 
maintenance under cART, this CD32a+ LILRA2+ CD57+ NKG2C+ 
TEff/Mem cluster displaying an activated profile may contribute to 
HIV persistence as an active reservoir. However, our analysis does 
not directly show the presence of higher levels of HIV DNA in 
CD4+ T cells belonging to this cluster. Moreover, total HIV DNA 
included integrated and non-integrated viral genomes coding for 
both competent and defective viruses. Therefore, future studies 
with purified CD32a+ CD4+ T cells are required to determine if 
there is an enrichment with HIV DNA within this cluster and if 
this DNA supports viral transcription.
Our analysis also revealed that numerous CD32a+ CD4+ T-cell 
clusters show expression of HLA-DR. These data are in agreement 
with a recent study demonstrating that a high portion of CD32+ 
CD4+ T  cells from HIV-infected patients under cART express 
HLA-DR (38). In this regard, most of the samples analyzed in 
our study were collected from HIV+ patients under cART, or in 
early phase of HIV infection (before cART), which is associated 
with enhanced immune activation and high viral load. Hence, 
it is likely that the samples acquired from HIV+ patients may 
account for the elevated number of HLA-DR+ CD32a+ CD4+ 
T-cell clusters found in our analysis. Moreover, concordantly with 
the study from Abdel-Mohsen et al., our results show that some 
activated, and not resting, CD32a+ CD4+ T-cell clusters positively 
correlated with the level of HIV DNA (38).
In conclusion, our results unravel the landscape and abun-
dance modifications of CD32a+ CD4+ T cells induced from early 
HIV infection to effective cART. Overall, this study brings a new 
view of CD32a+ CD4+ T cells during HIV infection that could be 
helpful in the discussions about HIV persistence and reservoirs.
MaTerials anD MeThODs
study subjects and ethics statements
All 12 subjects gave written informed consent to participate in 
the study. This study involved patients with primary HIV-1 
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infection enrolled in the French ANRS CO6 PRIMO cohort, 
which was approved by the Ethics Committee of Cochin 
Hospital. Patients were enrolled in the study if HIV infection 
was estimated to have occurred less than 30 days previously. All 
patients were antiretroviral naive and were negative for hepatitis 
B and C viruses. Even though the HIV+ patients show previ-
ous CMV infection (IgM−/IgG+), there were no clinical signs 
of reactivation of CMV since HIV diagnosis. Blood samples 
were collected at enrollment. Patients were then placed under 
antiretroviral treatment, and 12 months later, new blood samples 
were collected. The plasma HIV-RNA load was measured, as well 
as the number of total HIV-DNA copies per million PBMCs. 
CD4+ T cells were also counted for each sample before and after 
cART. All primary HIV-infected patients showed a viral load 
of fewer than 50 copies of viral RNA/ml and had more than 
500 CD4+ T cells/μl of blood once under cART. This study also 
involved blood samples of healthy subjects obtained from the 
Etablissement Français du Sang.
sample Processing and storage
PBMCs from each sample were isolated by Ficoll density gradient 
centrifugation. The number of viable PBMCs was determined 
using an automated blood counter (Vi-Cell/Beckman Coulter). 
Approximately 10 million PBMCs were put in a cryotube with 
90% heat-inactivated FBS (Eurobio) and 10% DMSO (Sigma). 
All samples were stored at −150°C in cryotubes.
hiV Dna Quantification
Total HIV DNA was quantified in PBMCs by qPCR (Biocentric, 
Bandol, France), as previously described (39).
antibodies
Antibodies (listed in Table S1 in Supplementary Material) were 
either pre-conjugated from the manufacturer (Fluidigm, San 
Francisco, CA, USA) or conjugated in-house with the appropriate 
metal isotopes. Between 200 and 400 µg pure mAbs (carrier-protein- 
free) from various manufacturers were coupled to Lanthanide 
from the MaxPar Antibody Labeling Kit X8 4Rxn (Fluidigm). 
Conjugated Abs were adjusted to 1 µg/µl in Ab Stabilizer Solution 
(Candor, Biosciences, Wangen, Germany), supplemented with 
0.01% sodium azide (Santa Cruz Biotechnology), and stored 
at 4°C. Abs conjugated in-house, as well as those obtained pre-
conjugated, were titrated and validated on samples that were 
processed identically to those used in the study.
cell staining
All samples were stained on the same day with the same batch 
of antibodies and acquired within 1 day to avoid batch effects 
and instrument signal fluctuations. Cells were thawed, and 
200 µl of the suspension containing 5 × 106 PBMCs transferred 
per well. PBMCs were incubated 20  min at 37°C with 1  µM 
Rhodium DNA-intercalator (Fluidigm). Cells were then washed 
twice with staining buffer (BD Biosciences) and stained with 
the primary surface antibody mix in a total volume of 60  µl 
staining buffer. Cells were incubated for 1 h at 4°C and washed 
twice. The secondary surface antibody mix was added to the 
cells in a total volume of 50 µl staining buffer and incubated 
for 15  min at 4°C. After two washes, cells were resuspended 
in 200  µl 1.6% PFA (EMS 15710) in PBS (Invitrogen) and 
incubated 20  min at 4°C. Cells were then washed twice in 
permeabilization buffer (eBioscience) and incubated 30  min 
at 4°C in 200  µl permeabilization buffer with 1  µM Iridium 
DNA-intercalator (Fluidigm). After two washes, PBMCs were 
incubated at 4°C overnight in 200  µl 1.6% PFA with 0.1  µM 
Iridium DNA-intercalator. For acquisition, cells were washed 
once with staining buffer, once with PBS, and twice with ddH2O 
and filtered through a cell strainer cap of a 5-ml polystyrene 
round-bottom tube (BD Biosciences). Fifty microliters of 
normalization beads (Fluidigm) were added to each sample. 
Then, samples were acquired using a mass cytometer (CyTOF; 
Fluidigm) following the standard procedure recommended by 
the manufacturer. An average of 207,233 ± 17,141 events was 
acquired per sample.
Data normalization
Raw cytometry profiles generated by CyTOF were normalized 
with the MatLab Compiler software normalizer (40), using the 
signal from the normalization beads, as recommended by the 
software developers.
Manual gating of cD45+ cD4+ T cells
Normalized events were gated to exclude doublets and triplets 
from the analysis by selecting cells with only one Iridium level. 
Then, beads added for normalization and dead cells were removed 
by selecting cells negative for Cerium (Ce140) and Rhodium, 
respectively. Finally, leukocytes were selected based on the posi-
tive expression of CD45. CD4+ T cells were then selected based 
on the expression of CD3, CD19, CD4, and CD8 (Figure S2 in 
Supplementary Material). After this gating strategy, an average of 
28,305 ± 3,375 cells remained per sample.
automatic identification of cell clusters
The automatic identification of cell clusters was performed using 
SPADE with the publicly available R package. We observed large 
differences in the number of manually gated CD4+ T cells in each 
sample, ranging from 6,864 to 53,599 cells. We avoided over-
representation of cell populations present in samples with a high 
number of cells by first randomly selecting 6,864 cells for each 
sample. This number corresponded to the sample with the lowest 
number of cells. These uniformly down-sampled events were 
up-sampled at the end of the SPADE analysis to better ascertain 
the phenotype of identified clusters. The SPADE heatmap was 
generated using 32 clustering markers (shown in blue Figure 1B). 
CD8 and CD19 were discarded from the SPADE analysis as we 
used them to pre-select CD4+ T  cells and CX3CR1 was not 
included in the set of clustering markers due to high heterogene-
ity of expression among samples. SPADE was parametrized to 
identify 350 cell clusters using a down-sampling parameter of 
40%. These parameters were found to be the most efficient to 
obtain clusters with uniform phenotypes with a sufficient number 
of associated cells by SPADEVizR (29). Uniform clusters were 
defined as those with unimodal density expression (Hartigan’s 
dip test) and a low range of expression (IQR < 2) for all clustering 
markers.
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Phenotypic characterization of identified 
cell clusters
The phenotypic categorization of the 350 cell clusters was per-
formed using SPADEVizR (29), based on the average median 
expression of each marker for all individuals. Marker expression 
was classified into five relative expression categories. The cate-
gories were defined based on the range of expression (5th to 
95th percentile) of each marker relative to that of CD4+ T cells. 
The marker intensity ranges were then divided into five uniform 
categories representing negative, low, medium, high, and very 
high marker expression and represented using a color scale 
ranging from white to dark red on the heatmaps. Hierarchical 
clustering was computed based on the Euclidian distance, using 
the complete linkage method.
Clusters displaying a myeloid phenotype were identified 
among the 350 cell clusters and removed from the SPADE analy-
sis, leaving only CD4+ T-cell clusters. In addition, clusters with 
less than 40 cells were also removed from the analysis, as their 
phenotypes could not be assessed accurately. Thus, 322 CD4+ 
T-cell clusters remained from the 350 SPADE clusters. Finally, 
CD4+ T-cell clusters displaying high or very high expression of 
CD32a (named CD32a+) were selected to perform all analyses.
Detailed phenotypic characterization of cluster five relative to 
other CD4+ T-cell clusters was performed using CytoCompare 
(41), based on the KS, using a threshold of 0.30.
identification of Dacs and correlating 
clusters
Differentially abundant clusters were identified using SPADEVizR 
(29), based on the percentage of cells in the clusters relative to 
total CD32a+ CD4+ T  cells by unpaired Student’s t-tests with 
a fold-change threshold of 2 and a p-value threshold of 0.05. 
Correlated clusters (CCs) were identified based on the percent-
age of cells in clusters relative to either CD32a+ CD4+ or CD4+ 
T cells that correlated with total HIV DNA levels. CCs were also 
identified using SPADEVizR and based on the Pearson correla-
tion coefficient with a threshold of 0.65 and a p-value < 0.05.
Data availability
Normalized cytometry profiles are available on the FlowRepository 
database through accession number FR-FCM-ZYGJ.
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FigUre s1 | Characterization of CD32a and CD32b antibody specificity by 
mass cytometry. Representative analysis of metal-conjugated CD32a-Dy161 
(upper panels) and CD32b-Sm149 (lower panels) antibody staining of 
monocytes, B cells, and CD4+ T cells performed on PBMCs from one  
healthy donor (out of six) using FlowJo software.
FigUre s2 | Gating strategy used to identify CD4+ T cells. “Singlets” were 
identified using cell length vs. Ir191-DNA intercalator and calibration beads  
were excluded (cells no beads). Living leukocytes were identified by selecting 
Rhodium (Rh103)Di-negative cells and then CD45+ cells. Finally, CD4+ T cells 
were identified by gating on CD3+ CD19− and then CD4+ CD8− cells.
FigUre s3 | Phenotypic landscape of CD4+ T-cell Spanning-tree Progression 
Analysis of Density-normalized Events (SPADE) clusters. A heatmap showing 
relative marker expression for SPADE clusters was generated. The mean of the 
median expression of each marker was determined and classified in a five-tiered 
color scale, from white (not expressed) to dark red (highly expressed), according 
to their range of expression (5th to 95th percentile) throughout the dataset. 
Clustering markers are shown in blue. Hierarchical clustering of both the cell 
clusters and clustering markers were performed and are represented by 
dendrograms.
FigUre s4 | Relative range of marker expression of Spanning-tree Progression 
Analysis of Density-normalized Events clusters. Graph showing the relative range 
of marker expression of clusters obtained after manual gating of CD4+ T cells. 
The range of expression for each marker (5th to 95th percentiles of expression 
throughout the dataset) are represented using a five-tiered color scale ranging 
from white (not expressed) to dark red (highly expressed). Clustering markers  
are shown in blue.
FigUre s5 | Cell number in each CD32a+ CD4+ T-cell cluster. This 
representation shows the number of cells associated with each CD32a+ CD4+ 
T-cell cluster, regardless of sample cell origin. Cluster names are indicated on the 
X-axis and the corresponding number of cells on the Y-axis. The size of the dots 
is proportional to the number of cells in the cluster.
FigUre s6 | Percentages of CD32a+ CD4+ TN, TCM, and TEff/Mem subsets among 
CD4+ T cells from HIV-infected patients and healthy donors. This representation 
shows the percentage of naive (TN), central memory (TCM), and effector/memory 
(TEff/Mem) CD4+ T cells among CD32a+ CD4+ T cells for primary HIV-infected 
patients before (primary HIV, red circles) and after 12 months of combination 
antiretroviral treatment (HIV cART, blue squares) and that of healthy donors 
(healthy, green triangles).
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FigUre s7 | Correlation analysis of total CD32a+ CD4+ T-cell cluster and cluster 
#5 cell abundances with HIV DNA levels. (a) Correlation analysis of total CD32a+ 
CD4+ T-cell cluster cell abundances with total HIV DNA levels. The HIV DNA load 
(log10 copies/106 PBMCs) for each sample are indicated on the X-axis, and the 
associated percentage of cells relative to CD4+ T cells for CD32a+ CD4+ T-cell 
clusters on the Y-axis. The Pearson correlation coefficient was equal to 0.4329 
(p = 0.0727). (B) Correlation analysis between cluster #5 cell abundance and  
HIV DNA levels. For each sample, the HIV DNA load (log10 copies/106 PBMCs)  
is indicated on the X-axis, and associated percentage of cells relative to CD32a+ 
CD4+ T cells for cluster #5 on the Y-axis. The Pearson correlation coefficient was 
equal to 0.6902 (p = 0.0015).
FigUre s8 | Percentages of cells associated with clusters #5, #258, #136,  
#86, #261, #241, #162, #312, #243, #188, and #142 among CD4+ T cells in 
HIV-infected patients and healthy donors. (a–D) Graphs showing the cell 
abundance relative to that of CD4+ T cells for clusters previously shown to be 
differentially abundant between HIV-infected patients (primary HIV and HIV  
cART) and healthy donors (healthy) among CD32a+ CD4+ T cells. (a,B) Clusters 
#5, #258, #136, #86, and #261 were significantly more abundant in Primary HIV 
(circle) and HIV cART (square) than Healthy (triangle) samples among CD32a+ 
CD4+ T cells. Cluster #5 was also more abundant in primary HIV than in HIV 
cART samples among CD32a+ CD4+ T cells. (c,D) Clusters #241, #162, #312, 
#243, #188, and #142 were significantly less abundant in primary HIV (circle)  
and HIV cART (square) than in healthy (triangle) samples among CD32a+ CD4+ 
T cells. Clusters #241 and #162 were also less abundant in primary HIV than  
in HIV cART samples among CD32a+ CD4+ T cells. Samples from the same 
HIV-infected patients are shown in the same color. For each condition, the  
mean cell abundance is indicated (black lines). Statistical differences between 
conditions were calculated using an unpaired Student’s t-test with a p-value 
threshold of 0.05.
FigUre s9 | Marker expression densities showing the phenotypic specificity of 
cluster #5 relative to whole CD4+ T-cell clusters. The expression densities of all 
clustering markers and CX3CR1 are shown for cluster #5 and whole CD4+ T-cell 
clusters. The marker expression densities for cluster #5 are shown in blue 
whereas the marker expression densities for all CD4+ T-cell clusters are shown in 
gray. The differences between marker expression densities were quantified using 
the Kolmogorov–Smirnov distances (KS).
TaBle s1 | Overview of the mass cytometry panel. The metal, antigen, clone, 
isotype, and supplier are indicated for each antibody. Non-clustering markers are 
indicated by a star.
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